Specifically, we identify that the basal cellular CYP3A4 metabolism can be differentially regulated by TME hypoxia and tissue stiffness, thus impacting the efficacy of commonly used HCC therapeutics. Here, CYP3A4 is linked to hepatocellular carcinoma.